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Human respiratory syncytial virus (RSV) sometimes causes acute and severe lower respiratory tract illness in infants and young
children.RSVstronglyupregulatesproinﬂammatorycytokinesandtheplatelet-activatingfactor(PAF)receptor,whichisareceptor
for Streptococcus pneumoniae, in the pulmonary epithelial cell line A549. Clarithromycin (CAM), which is an antimicrobial agent
and is also known as an immunomodulator, signiﬁcantly suppressed RSV-induced production of interleukin-6, interleukin-8, and
regulatedonactivation,normalT-cellexpressedandsecreted(RANTES).CAMalsosuppressedRSV-inducedPAFreceptorexpres-
sion and adhesion of ﬂuorescein-labeled S. pneumoniae cells to A549 cells. The RSV-induced S. pneumoniae adhesion was thought
tobemediatedbythehostcell’sPAFreceptor.CAM,whichexhibitsantimicrobialandimmunomodulatoryactivities,wasfoundin
this study to suppress the RSV-induced adhesion of respiratory disease-causing bacteria, S. pneumoniae,t oh o s tc e l l s .T h u s ,C A M
might suppress immunological disorders and prevent secondary bacterial infections during RSV infection.
1.Introduction
Human respiratory syncytial virus (RSV) is one of the most
important infectious agents causing acute lower respiratory
tract illness, such as bronchiolitis and pneumonia, in infants
and young children [1, 2]. Viral RNA generated during
RSV replication is recognized by host pattern recognition
molecules, such as Toll-like receptor 3 (TLR3) and retinoic
acid inducible gene-I (RIG-I), and it induces type I and type
III interferon [3, 4]. Transcriptional induction of proinﬂam-
matory cytokines, chemokines, and interferons is mediated
by NF-κB and interferon regulatory factors (IRFs) [5, 6].
These mediators are believed to contribute to the patho-
physiology of RSV infection, such as mucous hypersecretion,
swelling of submucous, and inﬁltration of lymphocytes,
neutrophils, eosinophils, and macrophages [7].
Frequently, there are coinfections with respiratory
viruses, including RSV, and bacteria that cause community-
acquired respiratory diseases, such as Streptococcus pneumo-
niae and Haemophilus inﬂuenzae. There is evidence for a
positive correlation between infections with S. pneumoniae
and RSV in the pathogenesis of otitis media, pneumonia,
and meningitis [8–11]. S. pneumoniae and H. inﬂuenzae
colonize to the host respiratory epithelium via host cell
surface receptors, such as the platelet-activating factor (PAF)
receptor [12–14]. These bacteria interact with the PAF
receptor via phosphorylcholine, which is a component of the
bacterial cell surface. Both live and heat-killed S. pneumoniae
cells show an increased adhesion to human epithelial cells
infected with RSV [15]. The upregulation of PAF receptor
expression that is induced by respiratory virus infections,
including those caused by RSV, results in the enhanced2 Mediators of Inﬂammation
adhesion of S. pneumoniae and H. inﬂuenzae to respira-
tory epithelial cells [15–17]. PAF receptor expression and
S.pneumoniaecelladhesionarealsoupregulatedbyexposure
to acid, which causes tissue injury and an inﬂammatory
response [18].
Clarithromycin (CAM) is 14-membered ring macrolide
a n t i b i o t i ct h a ta l s oa c t sa sab i o l o g i c a lr e a c t i o nm o d i ﬁ e rwi t h
anti-inﬂammatory properties. In Japan, CAM is applied to
diﬀuse panbronchiolitis, chronic bronchiolitis, otitis media,
and chronic sinusitis as an immunomodulator [19–21]. The
anti-inﬂammatory mechanism of CAM has not yet been
completely clariﬁed, but one of the important mechanisms
for its anti-inﬂammatory action is considered to be the
suppression of NF-κB[ 22–24].
R e c e n t l y ,w er e p o r t e dt h a tf o s f o m y c i n ,w h i c hi sa n
antibiotic, suppressed RSV-induced interleukin (IL)-8, reg-
ulated on activation, normal T-cell expressed and secreted
(RANTES), and the PAF receptor by suppressing NF-κB
activity [25, 26]. On the other hand, Wang et al. report that
CAM suppressed rhinovirus-induced Staphylococcus aureus
and H. inﬂuenzae adhesions to nasal epithelial cells [27]. So
we anticipate that CAM suppresses RSV-induced bacterial
adhesion to epithelial cells, because expression of PAF
receptor is controlled by NF-κB[ 28, 29]
In the present study, we examined the eﬀect of CAM
on cytokine production, PAF receptor expression, and RSV
infection-induced S. pneumoniae adhesion to respiratory
epithelial cells.
2. MaterialsandMethods
2.1. Viruses, Cell Lines, Bacteria, and Reagents. RSV strain
Long, human type II pulmonary epithelial cell line A549 and
S. pneumoniae strain R6 were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). RSV was
grown in HEp-2 cells. The virus titer of RSV was determined
using a plaque-forming assay with HEp-2 cells as the indi-
cator cells [25]. RSV infection to A549 cells was performed
at multiplicity of infection (MOI) of 1. CAM was donated
by Abbott Japan (Tokyo, Japan). A PAF receptor antago-
nist, 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho(N,N,N,-
trimethyl)-hexanolamine, was purchased from Calbiochem-
Merck (Darmstadt, Germany). An NF-κB inhibitor, pyrroli-
dine dithiocarbamate (PDTC), was purchased from Sigma-
Aldrich (St. Louis, MO).
2.2. Measurement of Cytokine Production. A549 cells were
infected with RSV at MOI of 1. After 24-hour infection, cul-
ture supernatants of RSV-infected and -uninfected cells were
collected. The amounts of IL-6, IL-8, and RANTES in the
culture supernatants were determined by enzyme-linked
immunosorbent assay (ELISA) (DuoSet ELISA development
kit, R&D systems, Minneapolis, MN).
2.3. Reverse Transcription-Polymerase Chain Reaction
(RT-PCR). Semiquantitative RT-PCR was carried out as
described previously [4, 30].
2.4. Flow Cytometry. The cell surface expression of the PAF
receptor was examined by ﬂow cytometry as previously
described [26]. The cells were harvested from culture ﬂasks
using a cell scraper and then incubated with 2.5μg/mL
of mouse anti-PAF receptor monoclonal antibody (11A4
(clone 21); Cayman Chemical, Ann Arbor, MI) or mouse
IgG2a, κ isotype control antibody (eBioscience, San Diego,
CA). After incubation at 4◦C for 30min, cells were col-
lected by centrifugation and washed once with Dulbecco’s
phosphate-buﬀered saline (PBS (−)). Cell suspensions were
incubated with a phycoerythrin-conjugated goat anti-mouse
IgG F(ab)2 fragment antibody (1:100 dilution) (Abcam,
Cambridge, UK)at4◦Cfor30min, andthe stainedcellswere
assessed with FACSCalibur (BD Bioscience, San Jose, CA).
2.5. Bacterial Adhesion Assay. S. pneumoniae adhesion was
assayed using ﬂuorescein-isothiocyanate- (FITC-) labeled
S. pneumoniae as previously described [26]. Brieﬂy, a bac-
terial suspension in 0.1M NaCl-50mM sodium carbonate
buﬀer (pH9.5) at 1 × 108 CFU/mL was prepared. FITC
isomer-I (Dojindo Laboratories, Kumamoto, Japan) was
added at a concentration of 1mg/mL, and the mixture was
incubated at 4◦C for 1h. The cells were washed three times
with PBS (−).
C A Mw a sa d d e dt om o n o l a y e r so fA 5 4 9c e l l s1hp r i o rt o
RSV infection. The A549 cells infected with RSV at an MOI
of 1 for 24h and uninfected A549 cells were incubated with
FITC-labeled S. pneumoniae cells at MOI of 10 for 30min
at 37◦C. For the control experiments, either 20μg/mL of the
P A Fr e c e p t o ra n t a g o n i s to r1 0μg/mL of the mouse anti-PAF
receptor monoclonal antibody (11A4(clone 21)) was added
totheA549 cells1h prior totheaddition of theFITC-labeled
bacteria. The cell monolayer was gently washed three times
with PBS (−) and observed by ﬂuorescence microscopy.
Alternatively, the cells were harvested with cell scraper and
thenassessedbyﬂowcytometryaspreviouslydescribed[26].
3. Results
First, we examined the eﬀect of CAM on RSV replication
in A549 cells. RSV infection to A549 cells was performed
at MOI of 1. After 24 and 36h of infection, signiﬁcant
alterations of the RSV titers or expression levels of G mRNA
were not observed by the addition of CAM even at a
concentration of 100μg/mL (Figure 1).
When A549 cells were infected with RSV at MOI of
1, RANTES, IL-8, and IL-6 were markedly induced. These
cytokine inductions were signiﬁcantly suppressed in the
presence of CAM in a dose-dependent manner (Figure 2).
The degree of suppression by CAM was less than that by an
NF-κB inhibitor, PDTC.
PAFreceptorexpressiononthecellsurfaceisupregulated
during RSV infection in A549 cells [26]. The RSV-induced
upregulationofthePAFreceptorwassigniﬁcantlysuppressed
by CAM and PDTC in a dose-dependent manner (Figure 3).
The degree of suppression by CAM was slightly less than that
by PDTC. Suppression of the PAF receptor expression was
also observed when A549 cells were posttreated with CAM
(4 or 12h after RSV infection) (data not shown).Mediators of Inﬂammation 3
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Figure 1: Eﬀects of CAM on RSV G mRNA expression (a) and production of infectious virus particles (b) in A549 cells infected with RSV.
One hour before RSV infection, CAM was added to A549 cell culture at the indicated concentration. A549 cells were infected with the RSV
at MOI of 1. (a) RT-PCR. After 24h of infection, total RNAs were extracted from the cells. The mRNA levels of RSV G were determined
by RT-PCR. The mRNA levels of human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were carried out as a control. (b) Plaque-
forming assay. After 24h and 36h infection, the culture supernatants were corrected. Virus titers in the supernatants were determined by
plaque-forming assay using Hep-2 cells as the indicator cell. Each experiment was performed in quadruplicate. The mean value and standard
deviation are shown.
We examined the adhesion of FITC-labeled S. pneumo-
niae cells to A549 cells by ﬂuorescence microscopy (Figure 4)
and ﬂow cytometry (Figure 5). RSV infection signiﬁcantly
enhanced the adhesion of S. pneumoniae to A549 cells,
and this enhancement was suppressed by adding a PAF
receptor antagonist (Figures 4 and 5)o ra n t i - P A Fr e c e p t o r
monoclonalantibody(datanotshown).Thisresultindicated
that the RSV-induced S. pneumoniae adhesion occurs via
the PAF receptor on A549 cells. The bacterial adhesion was
signiﬁcantly suppressed by CAM, as well as PDTC.
These lines of evidence conﬁrmed that the expression of
thePAFreceptorwasinducedbyRSVinfectionandindicated
thatthisinduction,andsubsequentRSV-inducedS.pneumo-
niae adhesion, can be suppressed by CAM treatment.
4. Discussion
Macrolides, with the exception of the 16-membered ring
type, have both anti-inﬂammatory and antibacterial func-
tions [20, 21]. One of the important mechanisms of anti-
inﬂammatory action is the suppression of NF-κBa c t i v a t i o n
[22–24]. Our recent studies show that RSV upregulates
proinﬂammatory cytokines, such as IL-6, and chemokines,
such as IL-8 and RANTES, in the respiratory epithelial cell
line A549. Furthermore, the induction of chemokines by
RSV is signiﬁcantly suppressed by an antibiotic, fosfomycin,
via suppression of NF-κBa c t i v a t i o n[ 25]. In the present
study, CAM was shown to suppress IL-6, IL-8, and RANTES,
which are induced by RSV infection, at concentrations of 10
and 100μg/mL. Patel et al. reported that the concentration of
CAM in ﬂuid of the bronchopulmonary epithelial lining was
34.2±5.16μg/mLat4h,23.01±11.9μg/mLat12hinhealthy
adults orally administered CAM 500mg [31]. We observed
that CAM did not aﬀect RSV replication even at a concen-
tration of 100μg / m L .H o w e v e r ,i ti sr e p o rt e dt h a tr e s p i r a t o ry
virus, such as RSV [32], rhinovirus [33, 34], and inﬂuenza
virus [35], replication is suppressed by 14-membered ring
macrolides, including CAM. The reasons of contradictory
results between the report of Asada et al. [32]a n do u r
present study have been unclear. These two studies used
diﬀerent types of epithelial cells and diﬀerent experimental
conditions of RSV infection. Asada et al. used primary
human tracheal epithelial cells, and in contrast we used A549
cell line. Asada et al. carry out infection at a lower titer of
RSV (10−3 TCID50/cell) and measuring virus titer at a longer
period (3–5 days) after infection. Our results indicated that
suppression of the RSV-induced cytokines by CAM was not
caused by the amount of replicated RSV. In other words,
CAM was suggested to have suppressive activity of cytokine
production independent of viral replication. Both IL-8
and RANTES, which are strongly upregulated during RSV
infection, play important roles in pathogenesis [36, 37].
IL-8 primarily activates neutrophils and promotes their
migration. RANTES is secreted from respiratory epithelial
cells and promotes migration of eosinophils, basophils,
monocytes, and neutrophils. In particular, RANTES is an
eﬃcient eosinophil chemoattractant involved in the patho-
genesis of asthma [38]. CAM has been suggested to suppress
the inﬂammatory disorders induced by RSV.
In the present study, we also observed that CAM sup-
pressed enhanced S. pneumoniae adhesion by RSV infection
in A549 cells. The RSV-induced S. pneumoniae adhesion
was mainly mediated by host PAF receptor, as indicated by
that suppressed by the PAF receptor antagonist and anti-
PAF receptor monoclonal antibody. The PAF receptor acts
as a receptor for S. pneumoniae and H. inﬂuenzae [12–
14]. Transcription of the PAF receptor gene is controlled by
NF-κB[ 28, 29]. We conﬁrmed it by that the RSV-induced
PAF receptor expression and S. pneumoniae adhesion were
s u p p r e s s e db ya nN F - κB inhibitor, PDTC. We revealed that
CAM also suppressed PAF receptor expression induced by
RSV infection and S. pneumoniae adhesion to RSV-infected
A549 cells. It should be caused by the suppression of4 Mediators of Inﬂammation
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Figure 2: Eﬀects of CAM and PDTC on RSV-induced RANTES (a),
IL-8 (b), and IL-6 (c) production in A549 cells. One hour before
RSV infection, CAM or PDTC is added to A549 cell culture at the
indicated concentration. A549 cells were infected with the RSV at
MOI of 1. After 24h of infection, the culture supernatants were
collected, and each cytokine in the supernatants was determined
by ELISA. The experiments were performed in triplicate. The mean
value and standard deviation were calculated. Statistical diﬀerence
was examined by Student’s t-test. ∗P<0.01 compared to cytokine
production without any reagent treatment in uninfected cells and
RSV-infected cells, respectively.
NF-κB activated by RSV infection. Recently, Wang et al.
[27] reported that CAM suppressed rhinovirus-induced
S. aureus and H. inﬂuenzae adhesions to nasal epithelial
cells. They show that the expressions of ﬁbronectin and
carcinoembryonic antigen-related cell adhesion molecule
(CEACAM), which act as receptors for S. aureus and
H. inﬂuenza, respectively, are induced by rhinovirus and
suppressed by CAM. The present study indicated that CAM
suppressed the PAF receptor-phosphorylcholine (host-
bacteria) interaction, which is enhanced by RSV infection,
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Figure 3: Eﬀect of CAM and PDTC on RSV-induced PAF receptor
expression in A549 cells. One hour before RSV infection, CAM or
PDTC is added to A549 cell culture at the indicated concentration.
The cells were infected with the RSV at MOI of 1. After 24h of
infection, the cells were collected and then stained with an anti-
PAF receptor antibody and phycoerythrin-labeled anti-mouse IgG
antibody (thick lines). The stained cells were analyzed by ﬂow
cytometry. Thin lines indicate the cells stained with an unrelated
isotype control antibody instead of the anti-PAF receptor antibody.
by inhibiting PAF receptor expression. CAM showed more
potent suppression of RSV-induced S. pneumoniae adhe-
sion and production of proinﬂammatory cytokines and
chemokines than fosfomycin, as we reported previously [25,
26]. Notably, CAM signiﬁcantly suppressed RSV-induced IL-
6 production, whereas fosfomycin did not signiﬁcantly [25].Mediators of Inﬂammation 5
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Figure 4: Suppression by CAM of RSV-induced adhesion of FITC-labeled S. pneumoniae to A549 cells, as observed by ﬂuorescence
microscopy. One hour before RSV infection, CAM (10 or 100μg/mL) or PDTC (50μM) was added to A549 cell monolayer. The cells were
infected with RSV at MOI of 1. After 24h of infection, FITC-labeled bacterial cells were added to the cell monolayer at MOI of 10, and
incubation was continued at 37◦C for 30min. A PAF receptor antagonist (20μg/mL) was added to the cell monolayer 1h before the addition
of labeled bacterial cells. The bacteria adhering to the A549 cell monolayer were visualized by ﬂuorescence microscopy.
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Figure 5: Suppression by CAM of RSV-induced adhesion of
FITC-labeled S. pneumoniae to A549 cells, as observed by ﬂow
cytometry. Experiments were performed as in Figure 5. The A549
cell monolayer incubated with FITC-labeled S. pneumoniae cells
was harvested by cell scraper and then applied to ﬂow cytometry.
Each experiment was performed in triplicate. The data present as
mean value ± standard deviation of the mean relative ﬂuorescence
intensity. ∗P<0.01 compared to RSV-infected cells without any
reagent treatment.
This ﬁnding may be caused by that CAM is more potent
than fosfomycin; however, the actual reason for this disparity
is not clear. The upregulation of PAF receptor expression
and the enhanced adhesion of pathogenic bacteria, such as
S.pneumoniae,torespiratoryepithelialcellsareconsideredto
be a major risk factor for secondary bacterial infections after
primaryrespiratoryviralinfections.CAMmaysuppressboth
secondary bacterial infections and immunological disorders
induced by RSV, without suppressing viral replication. Infec-
tion with other respiratory viruses, such as human parain-
ﬂuenza virus 3 [16] and rhinovirus [17], also upregulates
known receptors for the pathogenic bacteria, including PAF
receptor and S. pneumoniae adhesion. On the other hand,
inﬂuenza virus does not upregulate the known receptors for
bacteria,whereasbacterialadhesionisincreasedbytheinfec-
tion [16]. McCullers [39] reported that inﬂuenza-induced
bacterial adhesion to A549 cells was not inhibited by PAF
receptor antagonist, and the PAF receptor knock-out mice
did not show lower susceptibility to experimental secondary
pneumonia caused by S. pneunimoae following inﬂuenza
infection compared to the parent mice. Lines of evidence6 Mediators of Inﬂammation
suggestthatadherentinducingmechanismsofS.pneumoniae
to host respiratory epithelial cells are varied among viruses.
So CAM may not always suppress virus-induced pathogenic
bacteria adhesion.
5. Conclusions
We proposed that clarithromycin eﬃciently suppressed PAF
receptor-mediated Streptococcus pneumoniae adhesion to
respiratory epithelial cells as well as RSV-induced proinﬂam-
matorycytokineandchemokineproduction.Clarithromycin
may suppress secondary bacterial infections and immuno-
logical disorders during RSV infection.
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